SSSeyed Mehrab Safdari

Seyed Mehrab Safdari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seyed Mehrab Safdari has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Factor VII Padua: a systematic review of reported cases, diagnosis, clinical manifestations, and management strategies

    by Seyed Mehrab Safdari, Mahmood Shams, Samin Alavi, Akbar Dorgalaleh

    Factor VII (FVII) Padua is a rare inherited disorder caused by a missense variant in the F7 gene (Arg364Gln), resulting in variable FVII activity depending on the thromboplastin source used in assays. Although often linked to a hypercoagulable state, critical gaps remain in understanding its diagnosis, clinical manifestations, and geographic distribution. Following PRISMA guidelines, a systematic search of PubMed, Scopus, and Web of Science was conducted through February 2026 to identify studies reporting FVII Padua. Data on demographics, laboratory findings, and bleeding or thrombotic events were extracted from eligible publications. Thirty-six studies comprising 75 patients were identified. Most cases originated from Italy (22.6%), Iran (20%), the USA (17.3%), France (12%), and Brazil (9.3%). Ages ranged from 5 to 79 years. Sex information was available for 50 patients, of whom 27 (54%) were female and 23 (46%) were male. Prolonged prothrombin time and markedly reduced FVII activity using rabbit-brain thromboplastins were key diagnostic features, while human or recombinant thromboplastins showed milder reductions. Nearly half of the patients (n = 28; 49%) were asymptomatic; however, some experienced severe bleeding, including postpartum hemorrhage (n = 1; 1.7%) and gastrointestinal bleeding (GIB) (n = 3; ~5%). Thrombotic events were reported in six patients out of 13 (46%), including deep vein thrombosis (DVT) in two patients (33.3%) and pulmonary embolism (PE) in one patient (16.6%). This study demonstrates the global distribution and clinical heterogeneity of FVII Padua, emphasizing the need for thromboplastin-specific diagnostic evaluation and individualized management. Further research is essential to address existing diagnostic and therapeutic gaps.

  • Open Access

    Molecular diagnosis of inherited platelet disorders: a tale of two realities – advanced vs. resource-limited setting

    by Seyed Mehrab Safdari, Sina Jozdani, Mahsa Mottaghizadeh-Jazi, Maryam Shayanmanesh, Alireza Khanahmad, Mehdi Bakhtiyari Dovvom Beigi, Azadeh Rezazadeh, Shadi Tabibian

    Inherited platelet disorders are a heterogeneous group of rare conditions characterized by impaired platelet production or function, often leading to signi


  • Factor VII Padua in Iran: A Study on 150 Patients With Factor VII Deficiency

    by Seyed Mehrab Safdari, Mahmood Barati, Soudabeh Hosseini, Ebrahim Kalantar, Farhad Zaker, Akbar Dorgalaleh

    Introduction: Factor (F) VII Padua is an ultra‐rare type II FVII deficiency characterized by discrepancies in FVII activity across different thromboplastin types. Due to the high prevalence of consanguineous marriages in Iran, rare bleeding disorders, including FVII deficiency, are more common. Accurate identification of FVII Padua is critical to avoid inappropriate treatments and thrombotic risks. Aim: This study aimed to determine the incidence and clinical and laboratory characteristics of FVII Padua among Iranian patients with FVII deficiency. Method: One hundred fifty Iranian patients aged 18 years or older with confirmed FVII deficiency were included. PT testing was performed using rabbit brain, human placenta and recombinant human thromboplastins. Patients with PT discrepancies consistent with FVII Padua underwent genetic analysis of F7 exon 9 for the Arg364Gln mutation. Results: Thirteen patients (8.6%) exhibited PT patterns indicative of FVII Padua. HRM analysis identified nine heterozygous and two homozygous cases for the Padua variant; subsequently, sequencing analysis confirmed the Arg364Gln variant in two patients. Sequencing also revealed four additional variants in exon 9. The confirmed Padua cases presented diverse manifestations, ranging from asymptomatic to symptomatic, including bruising, epistaxis, gastrointestinal bleeding and gum bleeding. Conclusion: FVII Padua is relatively prevalent among Iranian patients with FVII deficiency . Molecular testing is essential for accurate diagnosis, enabling appropriate management and preventing unnecessary interventions. Tailored diagnostic strategies are crucial in regions with high consanguinity rates to optimize patient care and reduce thrombotic risks.

  • Open Access

    Fanconi Anemia: Challenges in Diagnosis and Management—A Case Series Report

    by Aziz Eghbali, Seyed Mehrab Safdari, Maedeh Yousefi Roozbahani, Khatereh Tavajohi, Soudabeh Hosseini

    Fanconi anemia (FA) is a rare inherited disorder characterized by congenital abnormalities, progressive bone marrow failure, and a predisposition to malignancies. Detecting FA can be challenging, as it involves identifying increased chromosomal sensitivity to DNA cross‐linking agents and detecting causative genetic variants via genome sequencing. We report two cases of siblings with FA, both confirmed to have the FANCD2 variant through whole‐exome sequencing (WES). The first patient presented with epistaxis, petechiae, ecchymosis, and lower limb edema. The second patient exhibited epistaxis, diabetes, developmental delay, and physical abnormalities. Interestingly, both patients had negative results on the initial chromosomal breakage test with mitomycin C, a commonly used diagnostic tool for FA. However, further investigation with WES revealed the presence of the FANCD2 variant, confirming the FA diagnosis. This case report highlights the challenges in diagnosing FA, particularly when initial screening tests yield negative results. Molecular genetic testing, such as WES, can provide a definitive diagnosis and guide appropriate management strategies. Early and accurate diagnosis is crucial for improving outcomes in individuals with this potentially fatal illness, as promising advancements in treatments such as hematopoietic stem cell transplantation and gene therapy offer hope for addressing FA.